Aligos Therapeutics, Inc. (ALGS) KPIs and segments
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Aligos Therapeutics's business
Coming soon
This tab will track the numbers specific to Aligos Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?